Goldman Sachs, RTX, and Abbott Featured in Latest Research Reports
The Zacks Research Daily has highlighted new reports on 16 significant stocks, including The Goldman Sachs Group, Inc. (GS), RTX Corp. (RTX), and Abbott Laboratories (ABT). These reports are part of a broader analysis that includes insights on micro-cap stocks such as NLI Holdings, Inc. (NL) and Precipio, Inc. (PRPO).
Goldman Sachs has shown strong performance, with its shares rising 33.7% over the past year, outpacing the Zacks Financial - Investment Bank industry. The firm has consistently exceeded earnings estimates and is focusing on sustainable revenue streams, bolstered by a robust investment banking backlog. However, rising expenses and dependence on international revenues pose challenges.
RTX has also performed well, with a 27.2% increase in share value compared to a decline in the broader Aerospace - Defense industry. The company benefits from a recovery in commercial aerospace and strong defense orders, maintaining a substantial backlog of $289 billion. Despite these positives, supply chain disruptions and geopolitical risks remain concerns.
Abbott's shares have declined by 18.9% over the past year, but the company maintains a balanced risk-reward profile with a diversified portfolio that supports steady growth. Key areas of strength include Medical Devices and Cancer Diagnostics, although challenges in pricing policies and integration risks persist.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News